Glioblastoma Multiforme Treatment - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509241507

Publication Date:

September 13, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Glioblastoma multiforme (GBM) is a fast-growing type of tumour of the brain or spinal cord. It is the most common type of primary malignant brain tumour in adults.
The global market for Glioblastoma Multiforme Treatment was estimated to be worth US$ 548.3 million in 2023 and is forecast to a readjusted size of US$ 996.4 million by 2030 with a CAGR of 8.8% during the forecast period 2024-2030
GBMs almost never spread outside of the brain, spine or central nervous system to other parts of the body. They are very challenging to treat because of their complex nature, which is why a great deal of research in the UK and around the world is focused on this tumour type.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Glioblastoma Multiforme Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Glioblastoma Multiforme Treatment by region & country, by Type, and by Application.
The Glioblastoma Multiforme Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glioblastoma Multiforme Treatment.
麻豆原创 Segmentation
By Company
Roche
Merck
Teva
AbbVie, Inc
Bristol-Myers Squibb
Sun Pharmaceutical
Arbor Pharmaceuticals
Segment by Type:
Bevacizumab (Avastin)
Carmustine (BiCNU)
Temozolomide (Temodar and Temodal and Temcad)
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Glioblastoma Multiforme Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Glioblastoma Multiforme Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Glioblastoma Multiforme Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Glioblastoma Multiforme Treatment Product Introduction
1.2 Global Glioblastoma Multiforme Treatment 麻豆原创 Size Forecast
1.3 Glioblastoma Multiforme Treatment 麻豆原创 Trends & Drivers
1.3.1 Glioblastoma Multiforme Treatment Industry Trends
1.3.2 Glioblastoma Multiforme Treatment 麻豆原创 Drivers & Opportunity
1.3.3 Glioblastoma Multiforme Treatment 麻豆原创 Challenges
1.3.4 Glioblastoma Multiforme Treatment 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Glioblastoma Multiforme Treatment Players Revenue Ranking (2023)
2.2 Global Glioblastoma Multiforme Treatment Revenue by Company (2019-2024)
2.3 Key Companies Glioblastoma Multiforme Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Glioblastoma Multiforme Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Glioblastoma Multiforme Treatment
2.6 Glioblastoma Multiforme Treatment 麻豆原创 Competitive Analysis
2.6.1 Glioblastoma Multiforme Treatment 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Glioblastoma Multiforme Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glioblastoma Multiforme Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Bevacizumab (Avastin)
3.1.2 Carmustine (BiCNU)
3.1.3 Temozolomide (Temodar and Temodal and Temcad)
3.2 Global Glioblastoma Multiforme Treatment Sales Value by Type
3.2.1 Global Glioblastoma Multiforme Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Glioblastoma Multiforme Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Glioblastoma Multiforme Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Glioblastoma Multiforme Treatment Sales Value by Application
4.2.1 Global Glioblastoma Multiforme Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Glioblastoma Multiforme Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Glioblastoma Multiforme Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Glioblastoma Multiforme Treatment Sales Value by Region
5.1.1 Global Glioblastoma Multiforme Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Glioblastoma Multiforme Treatment Sales Value by Region (2019-2024)
5.1.3 Global Glioblastoma Multiforme Treatment Sales Value by Region (2025-2030)
5.1.4 Global Glioblastoma Multiforme Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Glioblastoma Multiforme Treatment Sales Value, 2019-2030
5.2.2 North America Glioblastoma Multiforme Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Glioblastoma Multiforme Treatment Sales Value, 2019-2030
5.3.2 Europe Glioblastoma Multiforme Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Glioblastoma Multiforme Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Glioblastoma Multiforme Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Glioblastoma Multiforme Treatment Sales Value, 2019-2030
5.5.2 South America Glioblastoma Multiforme Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Glioblastoma Multiforme Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Glioblastoma Multiforme Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Glioblastoma Multiforme Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Glioblastoma Multiforme Treatment Sales Value
6.3 United States
6.3.1 United States Glioblastoma Multiforme Treatment Sales Value, 2019-2030
6.3.2 United States Glioblastoma Multiforme Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Glioblastoma Multiforme Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Glioblastoma Multiforme Treatment Sales Value, 2019-2030
6.4.2 Europe Glioblastoma Multiforme Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Glioblastoma Multiforme Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Glioblastoma Multiforme Treatment Sales Value, 2019-2030
6.5.2 China Glioblastoma Multiforme Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Glioblastoma Multiforme Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Glioblastoma Multiforme Treatment Sales Value, 2019-2030
6.6.2 Japan Glioblastoma Multiforme Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Glioblastoma Multiforme Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Glioblastoma Multiforme Treatment Sales Value, 2019-2030
6.7.2 South Korea Glioblastoma Multiforme Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Glioblastoma Multiforme Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Glioblastoma Multiforme Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Glioblastoma Multiforme Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Glioblastoma Multiforme Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Glioblastoma Multiforme Treatment Sales Value, 2019-2030
6.9.2 India Glioblastoma Multiforme Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Glioblastoma Multiforme Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Roche
7.1.1 Roche Profile
7.1.2 Roche Main Business
7.1.3 Roche Glioblastoma Multiforme Treatment Products, Services and Solutions
7.1.4 Roche Glioblastoma Multiforme Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Roche Recent Developments
7.2 Merck
7.2.1 Merck Profile
7.2.2 Merck Main Business
7.2.3 Merck Glioblastoma Multiforme Treatment Products, Services and Solutions
7.2.4 Merck Glioblastoma Multiforme Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Merck Recent Developments
7.3 Teva
7.3.1 Teva Profile
7.3.2 Teva Main Business
7.3.3 Teva Glioblastoma Multiforme Treatment Products, Services and Solutions
7.3.4 Teva Glioblastoma Multiforme Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 AbbVie, Inc Recent Developments
7.4 AbbVie, Inc
7.4.1 AbbVie, Inc Profile
7.4.2 AbbVie, Inc Main Business
7.4.3 AbbVie, Inc Glioblastoma Multiforme Treatment Products, Services and Solutions
7.4.4 AbbVie, Inc Glioblastoma Multiforme Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 AbbVie, Inc Recent Developments
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Profile
7.5.2 Bristol-Myers Squibb Main Business
7.5.3 Bristol-Myers Squibb Glioblastoma Multiforme Treatment Products, Services and Solutions
7.5.4 Bristol-Myers Squibb Glioblastoma Multiforme Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Bristol-Myers Squibb Recent Developments
7.6 Sun Pharmaceutical
7.6.1 Sun Pharmaceutical Profile
7.6.2 Sun Pharmaceutical Main Business
7.6.3 Sun Pharmaceutical Glioblastoma Multiforme Treatment Products, Services and Solutions
7.6.4 Sun Pharmaceutical Glioblastoma Multiforme Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Sun Pharmaceutical Recent Developments
7.7 Arbor Pharmaceuticals
7.7.1 Arbor Pharmaceuticals Profile
7.7.2 Arbor Pharmaceuticals Main Business
7.7.3 Arbor Pharmaceuticals Glioblastoma Multiforme Treatment Products, Services and Solutions
7.7.4 Arbor Pharmaceuticals Glioblastoma Multiforme Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Arbor Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Glioblastoma Multiforme Treatment Industrial Chain
8.2 Glioblastoma Multiforme Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Glioblastoma Multiforme Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Glioblastoma Multiforme Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Roche
Merck
Teva
AbbVie, Inc
Bristol-Myers Squibb
Sun Pharmaceutical
Arbor Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.